Table K14Comparing PCA3 and EVN scores in matched studies via AUC analysis to correctly diagnose prostate cancer, as defined by a positive needle biopsy

AuthoraYearNumberInitial BxPCA3 AUCEVN AUCDifferencebP-valuec
Perdona6201121861%0.82800.71500.11300.003
Ankerst12200844381%0.66500.65300.0120NS
FDA Summary1120124640%0.70700.65300.0540<0.05
All1125

Bx = biopsy, AUC = area under the curve, ‘-‘ = no value reported

a

Shaded rows indicate studies focusing on the ‘grey zone’ of tPSA.

b

PCA3 AUC – EVN AUC

c

Reported p-value for the comparison of the two AUCs computed among the same set of men

From: Appendix K, Summary of the Remaining Combined Analyses for KQ 1 and KQ 2

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer
PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 98.
Bradley LA, Palomaki G, Gutman S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.